Neutralizing HMGB1 suppresses tumor angiogenesis in ESCC

Neutralizing HMGB1 suppresses tumor angiogenesis in ESCC

arigo is proud to announce that our HMGB1 Neutralizing antibody (ARG66714) has been used for investigating the peritumoral B cells drived proangiogenic responses in esophageal squamous cell carcinoma (ESCC).

Kam et al. reported that high proportions of B cells are found in the peritumoral region of ESCC. They found that ESCC-derived HMGB1 not only promotes B-cell proliferation and migration but also drives B cells toward a proangiogenic profile. arigo's HMGB1 Neutralizing antibody (ARG66714) played a key role to demonstrate that B-cell promotes angiogenesis in a HMGB1-dependent manner to fuel esophageal tumor growth in vivo. (Kam et al., (2021) Angiogenesis. 2021 Oct 6: 1-23.)


HMGB1 Neutralizing antibody [SQab20175] (ARG66714)

● Specific Mouse mAb
● In vitro & in vivo validation
● Works on human and mouse cells
● Good for ELISA, FACS, Neut, WB


▶ More information about HMGB1

Total solution for HMGB1 research
HMGB1 in inflammation
Dual roles of HMGB1 in TME (tumor microenvironment)
Exsosomal HMGB1 for ICD research
HMGB1 and COVID-19